Natural History of Acquired and Inherited Bone Marrow Failure Syndromes

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2-99
SponsorNational Heart, Lung, and Blood Institute (NHLBI)

About this trial

Background:

Bone marrow failure diseases are rare. Much is known about the diseases at the time of diagnosis, but long-term data about the effects of the diseases and treatments are lacking. Researchers want to better understand long-term outcomes in people with these diseases.

Objective:

To follow people diagnosed with acquired or inherited bone marrow failure disease and study the long-term effects of the disease and its treatments on organ function.

Eligibility:

People aged 2 years and older who have been diagnosed with acquired or inherited bone marrow failure or Telomere Biology Disorder. First degree family members may also be able to take part in the study.

Design:

Participants will be screened with a medical history, physical exam, and blood tests. They may have a bone marrow biopsy and aspiration. For this, a large needle will be inserted in the hip through a small cut. Marrow will be drawn from the bone. A small piece of bone may be removed.

Participants may also be screened with some of the following:

Cheek swab or hair follicle sample

Skin biopsy

Urine or saliva sample

Evaluation by disease specialists (e.g., lung, liver, heart)

Imaging scan of the chest

Liver ultrasounds

Six-Minute Walk Test

Lung function test

Participants will be put into groups based on their disease. They will have visits every 1 to 3 years. At visits, they may repeat some screening tests. They may fill out yearly surveys about their medicines, transfusions, pregnancy, bleeding, and so on. They may have other specialized procedures, such as imaging scans and ultrasounds.

Participation will last for up to 20 years.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age >=2 years

Diagnosis of acquired or inherited bone marrow failure or ineffective hematopoiesis or TBD (see below for cohort 3 specific criteria)

Ability and willingness to come to the NIH CC for consultation and testing

Ability of subject or Legally Authorized Representative (LAR) to understand the investigational nature of the protocol and their willingness to sign a written informed consent document

Disqualifiers

None

Trial population

Subjects with Severe Aplastic Anemia, other acquired marrow failure syndromes, and inherited marrow failure syndromes. Family members of subjects with either suspected or confirmed inherited bone marrow failure.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

1,000 Participants
are grouped into 5 trial groups
Group A: Cohort 1
Group B: Cohort 2
Group C: Cohort 3
Group D: Cohort 4
Group E: Cohort 5

Trial outcomes

Primary outcomes

1

Cohort 4: Rate of progression to transfusion dependent marrow failure, marrow failure requiring therapeutic intervention (such as medical therapy or HSCT) or the progression to hematological malignancy

Rate of progression to transfusion dependent marrow failure, marrow failure requiring therapeutic intervention (such as medical therapy or HSCT) or the progression to hematological malignancy.

Time frame
20 years
2

Cohort 3: Development of cytopenias, lung disease or liver disease, or (if present at baseline) characterization, and rate of progression of cytopenias, lung disease or liver disease in TBD patients and looking at their overall contribution to m...

Development of cytopenias, lung disease or liver disease, or (if present at baseline) characterization, and rate of progression of cytopenias, lung disease or liver disease in TBD patients and looking at their overall contribution to morbidity and mortality.

Time frame
20 years
3

Cohort 1: Rate of relapse and clonal evolution in previously treated patients

Rate of relapse and clonal evolution in previously treated patients

Time frame
20 years
4

Cohort 2: Rate of progression requiring therapeutic intervention

Rate of progression (cytopenias or clonal evolution) requiring therapeutic intervention.

Time frame
20 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.